Are you Dr. Catchatourian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1900 W Polk St
Suite 751
Chicago, IL 60612Phone+1 312-854-7257Fax+1 312-864-9002
Summary
- Dr. Rosalind Catchatourian, MD is an oncologist in Chicago, Illinois. She is currently licensed to practice medicine in Illinois and California.
Education & Training
- University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 1972 - 1975
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1970 - 1972
- West Suburban Medical CenterInternship, Transitional Year, 1969 - 1969
- National Taiwan University College of MedicineClass of 1967
Certifications & Licensure
- CA State Medical License 1975 - Present
- IL State Medical License 1972 - 2020
Clinical Trials
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
- S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Publications & Presentations
PubMed
- 51 citationsA randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.John Mascarenhas, Heidi E Kosiorek, Josef T Prchal, Alessandro Rambaldi, Dmitriy Berenzon
Blood. 2022-05-12 - 118 citationsPegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Dmitriy Berenzon
Blood. 2019-10-31 - 93 citationsAdministration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.Jessica K. Altman, Alfred Rademaker, Elizabeth H. Cull, Bing Bing Weitner, Yishai Ofran
Leukemia Research. 2013-09-01
Professional Memberships
- Member